Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. faces severe regulatory penalties for financial fraud involving false records in multiple annual reports from 2019 to 2021 and 2023, marking it as a significant case of financial misconduct in the A-share market [2][3]. Group 1: Regulatory Actions - On December 19, Guizhou BaiLing received an administrative penalty notice from the Guizhou Securities Regulatory Bureau, proposing a total fine of 25.6 million yuan, including 10 million yuan for the company and 5 million yuan for its chairman, Jiang Wei [2][5]. - The company is required to correct its violations and has been warned, with penalties also proposed for 10 responsible individuals totaling approximately 15.6 million yuan [5][6]. - Jiang Wei, as the chairman, is subject to a 10-year ban from the securities market due to his knowledge of the financial misconduct and failure to act [5]. Group 2: Financial Misconduct Details - Guizhou BaiLing's financial misconduct involved underreporting sales expenses by 350.12 million yuan, 240.81 million yuan, and 63.79 million yuan for the years 2019, 2020, and 2021 respectively, leading to inflated profits of the same amounts, which represented 95.73%, 115.35%, and 45.04% of the reported profit totals for those years [4]. - In 2023, the company also overstated sales expenses by 459.41 million yuan, which accounted for 93.17% of the reported profit total for that year [4]. Group 3: Investor Implications - Investors who suffered losses due to Guizhou BaiLing's financial fraud may pursue legal action for compensation, particularly those who bought shares between April 30, 2020, and November 8, 2024, and sold or held shares thereafter [7][9]. - The company's stock will be suspended for one day on December 22 and will resume trading on December 23 under a new designation "ST BaiLing," indicating financial distress [9].

中经记者 孙汝祥 夏欣 北京报道 对此，贵州证监局拟决定对贵州百灵责令改正，给予警告，并处以1000万元罚款；对时任公司董事长姜 伟，给予警告，并处以500万元罚款，同时采取10年证券市场禁入措施；对时任公司董事、总经理和董 事会秘书牛民，给予警告，并处以350万元罚款；对其他8名责任人给予警告，合计处以710万元罚款。 值得一提的是，贵州证监局拟决定的对贵州百灵1000万元罚款、姜伟500万元罚款，皆为顶格处罚。 《证券法》第一百九十七条第二款规定，信息披露义务人报送的报告或者披露的信息有虚假记载、误导 性陈述或者重大遗漏的，责令改正，给予警告，并处以100万元以上1000万元以下的罚款；对直接负责 的主管人员和其他直接责任人员给予警告，并处以50万元以上500万元以下的罚款。 贵州百灵（002424.SZ）12月19日晚间公告，公司及相关当事人收到《行政处罚事先告知书》。贵州证 监局拟对公司及10名责任人合计处以2560万元罚款。其中，拟对贵州百灵及董事长姜伟作出顶格处罚， 分别罚款1000万元、500万元。 经查，贵州百灵涉嫌违法事实为，未以权责发生制为核算基础，按收入成本费用配比原则计提销售费 用，少 ...

据红星资本局报道，12月19日，贵州百灵发布公告，公司及相关当事人已收到贵州证监局送达的《行政 处罚事先告知书》。经查，贵州百灵在2019年至2023年期间存在财务造假行为，具体表现为：2019年少 计销售费用3.5亿元，相应多计利润3.5亿元，占当期报告记载利润总额（绝对值）的95.73%；2020年少 计销售费用2.4亿元，多计利润2.4亿元，占比达115.35%；2021年少计销售费用6379.16万元，多计利润 6379.16万元，占比45.04%；2023年多计销售费用4.59亿元，少计利润4.59亿元，占比93.17%。上述财务 造假行为，导致贵州百灵披露的2019年，2020年，2021年，2023年年报存在虚假记载。 对此，贵州证监局拟对贵州百灵作出责令改正、给予警告并处以1000万元罚款的处罚。同时，对公司董 事长姜伟、总经理牛民等10名相关当事人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证 券市场禁入措施。 与此同时，贵州百灵公告称，公司股票自2025年12月22日（星期一）开市起停牌一天，并于2025年12月 23日（星期二）开市起复牌。公司股票在2025年12月23日（ ...

Core Viewpoint - Three A-share listed companies have received administrative penalty notices from regulatory authorities for financial fraud, highlighting the ongoing strict regulatory environment in the market [1][6]. Group 1: Company Specifics - Guizhou Bailing announced on December 19 that it received an administrative penalty notice from the Guizhou Securities Regulatory Bureau, indicating that its annual reports for 2019, 2020, 2021, and 2023 contained false records [2][6]. - The company was found to have understated sales expenses by a total of 654.726 million yuan from 2019 to 2021 and overstated sales expenses by 459.411 million yuan in 2023, leading to a fine of 10 million yuan and warnings for responsible individuals [2][6]. - Funi Oriental also received a notice on December 19, stating that its subsidiary engaged in practices that led to inflated profits of approximately 35.8 million yuan in 2020, which was 120.18% of the reported profit for that year [3][4]. Group 2: Regulatory Environment - The recent penalties reflect a zero-tolerance approach by regulatory authorities towards securities violations, emphasizing the importance of compliance in the financial market [6]. - The regulatory actions against Guizhou Bailing and Funi Oriental demonstrate the ongoing efforts to combat financial fraud, which is seen as a significant threat to market integrity [6]. Group 3: Investor Implications - Investors may seek compensation for losses incurred due to the fraudulent activities of these companies, but they must establish a causal relationship between the false statements and their financial losses [7][9]. - Legal experts indicate that successful claims for compensation are contingent upon meeting specific criteria, including the timing of stock purchases relative to the fraudulent activities [9][10]. - Historical cases, such as the compensation awarded to investors in Kangmei Pharmaceutical, illustrate the potential for successful claims against companies found guilty of financial misconduct [8][10].

【#贵州百灵3年虚增利润6.5亿被罚1000万#】#贵州百灵董事长等10人被罚合计1560万##贵州百灵3年虚 增利润6.5亿#12月19日，贵州百灵发布公告，公司及相关当事人已收到贵州证监局送达的《行政处罚事 先告知书》。经查，贵州百灵在2019年至2023年期间存在财务造假行为，具体表现为：2019年少计销售 费用3.5亿元，相应多计利润3.5亿元，占当期报告记载利润总额（绝对值）的95.73%；2020年少计销售 费用2.4亿元，多计利润2.4亿元，占比达115.35%；2021年少计销售费用6379.16万元，多计利润6379.16 万元，占比45.04%；2023年多计销售费用4.59亿元，少计利润4.59亿元，占比93.17%。上述财务造假行 为，导致贵州百灵披露的2019年，2020年，2021年，2023年年报存在虚假记载。 对此，贵州证监局拟对贵州百灵作出责令改正、给予警告并处以1000万元罚款的处罚。同时，对公司董 事长姜伟、总经理牛民等10名相关当事人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证 券市场禁入措施。 与此同时，贵州百灵公告称，公司股票自2025年12月22日 ...

Core Viewpoint - Regulatory authorities have issued administrative penalties to four listed companies, emphasizing a strong stance against financial fraud and violations, regardless of the methods used or the amounts involved [2] Group 1: Company-Specific Violations - Far East Intelligent (ST远智) engaged in financial misconduct by using forged acceptance certificates to prematurely recognize revenue from elevator sales, resulting in inflated revenues of approximately 123 million yuan, 66.23 million yuan, and 138 million yuan from 2019 to 2021 [3][4] - Fuhua Oriental (福能东方) was involved in a scheme with its subsidiary, where it falsely recognized receivables and inflated profits by 35.8 million yuan in 2020, which accounted for 120.18% of the company's reported profit for that year [4][5] - Guizhou Bailin (贵州百灵) failed to adhere to accounting standards, leading to a misstatement of sales expenses and inflated profits by 350 million yuan in 2019 and 240 million yuan in 2020, among other discrepancies [7][8] - Bayi Steel (八一钢铁) was found to have significant non-operating fund transactions with its controlling shareholder, failing to disclose approximately 3.675 billion yuan in transfers in 2022 alone [9] Group 2: Regulatory Actions and Penalties - Far East Intelligent received a warning and a fine of 6 million yuan, with penalties imposed on its executives ranging from 200,000 to 3 million yuan [4] - Fuhua Oriental was fined 6.5 million yuan and received a warning, with its stock facing additional risk warnings due to the violations [5][6] - Guizhou Bailin faced a fine of 10 million yuan, and its chairman is subject to a 10-year ban from the securities market due to severe violations [7][8] - Bayi Steel was fined 3 million yuan, while its controlling shareholder was fined 4 million yuan for failing to disclose significant financial transactions [9]

12月19日晚，中国证监会贵州监管局(下称"贵州证监局")发布通报，近日，对贵州百灵（002424）企业集团制药股份有限公司(下称"贵州百灵")涉嫌定期 报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 贵州证监局表示，财务造假是严重破坏市场"三公"原则，侵害投资者合法权益的毒瘤，将坚决贯彻证监会党委的各项决策部署，着力提升监管执法的有效 性和震慑力，坚持对财务造假"零容忍"打击的鲜明立场，聚焦打大、打恶、打重点，紧盯实控人、控股股东、董事、高管等"关键少数"和中介机构"看门 人"，严格执法、秉公执法，坚决做到监管"长牙带刺"、有棱有角，以有力监管执法护航贵州资本市场行稳致远。 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至2021年期间少计销售费用，累计虚增利润65472.60 万元，2023年多计销售费用，虚减利润45941.10万元。对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正， 给予警告，处以1000万元罚款，拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证券市场禁入措施。 ...

12月19日，贵州百灵公告，公司及相关当事人当日收到贵州证监局出具的《行政处罚事先告知书》。经 查明，2019年至2021年，贵州百灵少计销售费用，累计虚增利润65472.60万元；2023年，公司多计销售 费用，虚减利润45941.10万元。基于此，监管部门拟对贵州百灵及10名董高人员给予警告，并合计罚款 2560万元。 业内人士表示，贵州百灵一案再次表明，无论是"硬造假"，还是"软造假"，监管的态度一以贯之：打假 保真，给投资者一个真实的上市公司；造假必重罚，严重造假要退市。 公司多年财务数据失真 除贵州百灵自身外，目前披露的拟处罚对象涉及10位当事人。在处罚力度上，根据当事人违法行为的事 实、性质、情节与社会危害程度，量体裁衣。其中，对贵州百灵责令改正，给予警告，并处以1000万元 罚款；对公司董事长姜伟给予警告，并处以500万元罚款。除被顶格罚款外，姜伟还面临10年证券市场 禁入处罚。 资本市场绝非"法外之地" 近年来，监管以雷厉风行之势，接连查处多起财务造假大案。 据媒体统计，截至2025年8月31日，证监会2024年以来累计查处67家退市公司违法行为，其中对46家已 做出最终行政处罚决定。截至20 ...

上海一位财务专家向中国证券报记者解释："销售费用是期间费用，跟当期收入无关。举例来说，A公 司期间内发生销售费用1000万元，包括销售人员工资、广告宣传费用等明细，但公司不把1000万元全部 入账，只把其中一部分去跟收入配比入账，会'增厚'A公司利润。" ● 本报记者 吴科任 12月19日，贵州百灵公告，公司及相关当事人当日收到贵州证监局出具的《行政处罚事先告知书》。经 查明，2019年至2021年，贵州百灵少计销售费用，累计虚增利润65472.60万元；2023年，公司多计销售 费用，虚减利润45941.10万元。基于此，监管部门拟对贵州百灵及10名董高人员给予警告，并合计罚款 2560万元。 业内人士表示，贵州百灵一案再次表明，无论是"硬造假"，还是"软造假"，监管的态度一以贯之：打假 保真，给投资者一个真实的上市公司；造假必重罚，严重造假要退市。 公司多年财务数据失真 贵州证监局认为，在上述年度，贵州百灵违反《企业会计准则-基本准则》，未以权责发生制为核算基 础，按收入成本费用配比原则计提销售费用。 国浩律师事务所合伙人黄江东团队认为，我国在证券违法犯罪治理方面进入了"从严惩处、重典治市"的 新阶段。这 ...

Core Viewpoint - Guizhou Bailing, known as the "first stock of herbal medicine," has been penalized for financial fraud, including a cumulative profit inflation of 655 million yuan from 2019 to 2021 and a profit reduction of 459 million yuan in 2023, leading to a maximum fine of 10 million yuan and severe penalties for its controlling shareholder and other executives [1][2][3]. Summary by Sections Reasons for Financial Fraud - The core reason for the financial fraud is the survival anxiety of the company, which resorted to "robbing Peter to pay Paul" due to dire circumstances [1]. - The company inflated profits to maintain stock prices and investor confidence, avoiding delisting due to continuous losses. In 2019, profit inflation accounted for 95.73% of total profits, and in 2020, it exceeded 115% [2]. - The controlling shareholder's family faced a financial crisis, having previously cashed out billions through stock sales but now burdened with debts from various investments. As of September 2025, all shares held by the controlling shareholder were pledged, and a lawsuit could lead to a change in ownership [3][4]. - The company had a history of regulatory issues, receiving multiple warnings and penalties, which fostered a sense of complacency among responsible parties, leading to the belief that they could evade consequences through "technical adjustments" [5][6]. Operational Issues - The company faces significant operational challenges, primarily due to its reliance on a narrow product range, with over 80% of revenue coming from traditional Chinese medicine. Key products are experiencing intense market competition and price restrictions, resulting in a 37.07% revenue decline in this segment by mid-2025 [7]. - There is a heavy emphasis on marketing over research and development, with sales expenses in 2022 reaching 1.238 billion yuan, nearly ten times the R&D investment. In 2024, marketing expenses were 1.419 billion yuan, while R&D spending decreased by 26.79% to only 60.98 million yuan, representing less than 1.6% of revenue [8][10]. - Internal controls are weak, with the company failing to adhere to basic accounting principles, leading to distorted financial data. The personal issues of the controlling shareholder are closely tied to the company's operations, resulting in poor governance [10]. Impact of the Scandal - The penalties have severely impacted the company's reputation and financing capabilities, with stock price fluctuations limited to 5% following the "ST" designation. The company's market value has shrunk by 60% from its peak, now standing at 7.449 billion yuan [11][13]. - Investors face challenges in seeking redress, as many view the situation as a "black swan" event. Although legal action is possible, the process is lengthy and uncertain regarding compensation [14]. - Short-term recovery appears unlikely, despite efforts to reform and develop new products. The company's financial condition and governance issues hinder its ability to support a transformation strategy [15].